⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SLNG News
Stabilis Solutions, Inc. Common Stock
Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease
businesswire.com
SLNG
Form 8-K
sec.gov
SLNG
Stabilis Solutions Announces Second Quarter 2026 Results
accessnewswire.com
SLNG
Form 8-K
sec.gov
SLNG
Stabilis Solutions Announces Second Quarter 2026 Conference Call and Webcast Date
accessnewswire.com
SLNG
Form 8-K
sec.gov
SLNG
Form 8-K
sec.gov
SLNG
Form 8-K
sec.gov
SLNG
Form 8-K
sec.gov
SLNG
Stabilis Solutions Announces First Quarter 2026 Results
accessnewswire.com
SLNG